Status:
COMPLETED
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Aspergillosis
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant). This study will s...
Detailed Description
The duration of treatment is 12 months.
Eligibility Criteria
Inclusion
- Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy.
- The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU hCG prior to enrollment.
Exclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00076869
Start Date
January 1 2003
End Date
August 1 2005
Last Update
January 13 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.